Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Currently ACY-1215 is in phase I clinical trials in combination with Lenalidomide and Dexamethasone for patients with multiple myeloma
supernatants from 3-O-C12-HSL-stimulated cells induced neutrophil chemotaxis
W-7 antagonizes the smooth muscle contraction through the inhibition of the initial increase in the P-LC phosphorylation
RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases
PC-766B Catalog No.:M22658-C Currently ACY-1215 is in phasePC 766B is a macrolide antibiotic existed in anactinomycete strain SC 4710. PC 766B was active against Gram positive bacteria, and some fungi and yeasts, yet inactive against Gram negative bacteria. PC 766B exhibited potent cytotoxicity against murine tumor cell lines in vitro. The IC50 values against P388 leukemia and B16 melanoma were 0. 1 and 0. 5 ng ml, respectively . Intraperitoneal administration of PC 766B (0. 25mg kg day) showed in vivo